Metabolic issues are a large part of type 2 diabetes mellitus (T2DM), and lipid disorders in particular place these patients at elevated risk for cardiovascular morbidity and motality.
Three presentations at the 2015 American Association of Clinical Endocrinologists annual meeting in Nashville, Tenn, focused on research into assessment and treatment of lipid abnormalities and are highlighted in this short slide presentation:
♦ Neck circumference may be a better indicator of metabolic disturbances than waist circumference
♦ The novel lipid- and glucose-lowering drug saroglitazar appears to be an effective therapeutic option for diabetic dyslipidemia not controlled by statins
♦ Three-quarters of T2DM patients at very high risk for cardiovascular disease (CVD) may be intolerant of statin treatment.